Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com.

*Afatinib and nintedanib are investigational compounds; their safety and efficacy have not been established.

References 

[1] Wu, Y., MD.  LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) vs gemcitabine/cisplatin
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... On Aug. 20, at its annual meeting in ... voted on and approved a delegate resolution opposing the ... Cannabis Corp., a leading Canadian licensed producer of medicinal ... The CMA is quite right to point out that ... material, including medicinal cannabis. While some patients, particularly those ...
(Date:8/22/2014)... -- MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and ... medical device company, have formally agreed to an ... system in Japan . It is anticipated ... Japan in the latter half of 2015. ... portfolio in endoscopic surgery market in Japan ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The particulate ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... September 9, 2011 The Board of the ... today it agreed to ratify the proposal of the US ... package, designed with the help of EFCG and US industry ... User Fees Act (GDUFA). GDUFA requires the FDA ...
... Advanced Wound Management division of Smith & Nephew (LSE: SN; ... studies on a range of products and therapies from their ... RENASYS* wound care portfolio. The data demonstrate advanced healing strategies ... products. Results of the studies are being presented at the ...
Cached Medicine Technology:European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 3Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 4
(Date:8/22/2014)... Worth, FL (PRWEB) August 22, 2014 Millennium ... of marijuana, resulting in a high level of drug use ... all ages fight against drug addiction and work to minimize ... highest levels of alcohol and drug addiction in history. According ... 2012, an estimated 23.9 million Americans aged 12 or older—or ...
(Date:8/22/2014)... Norton HealthDay Reporter ... number of Americans on work disability chronically use powerful ... found that between 2007 and 2011, about 44 percent ... prescribed narcotic painkillers each year. And the percentage using ... to 23 percent in 2011. Experts said ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... August 22, 2014 Natural Clear Vision ... to restore his own vision from legally blind to perfect ... an investigative review. , “There is a huge portion ... for everyday function, and most people just think that’s the ... eye surgery that can be pretty risky at times,” reports ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced non-small ... progression free survival (PFS) in epidermal growth factor ... treated Asian patients. Also, BIM deletion independently predicts ... The BIM protein can activate the programmed cell ... cells. BIM deletion has been detected in 12.8% ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... Racing may be a sport where the,drivers are ... to be as intense as any professional athlete. Hitting ... mentally tough, as well,physically fit, so many look to ... See video from General Motors (NYSE: GM ...
... OSTE ), a global leader in OsteoBiologic ... today that Sam Owusu-Akyaw,Osteotech,s President and Chief Executive ... Technologies Conference in New York.,Mr. Owusu-Akyaw is scheduled ... September 11, 2007. Osteotech, Inc., headquartered in ...
... A new study shows the number of drug-therapy related ... Drug Administration (FDA) nearly tripled between 1998 and 2005. ... Medicine and colleagues reviewed serious and fatal drug events ... consumers, health professionals and drug manufacturers, and found that ...
... disease, researchers say , , MONDAY, Sept. 10 (HealthDay News) -- ... study suggests. , "The intake of usual doses of ... death," said lead researcher Dr. Philippe Autier, from the International ... new finding, published in the Sept. 10 issue of the ...
... the Association for Assessment and Accreditation of Laboratory ... standard for animal care facilities, AAALAC accreditation is ... the humane care and use of animals in ... involves a comprehensive review by AAALAC evaluators, who ...
... Plan Cost Advisor helps consumers determine out-of-pocket health care ... Blue Shield has,introduced a new tool to help consumers ... their needs. The Plan Cost Advisor is available,to consumers ... plan is often intimidating to consumers," said Kim,Bellard, Vice ...
Cached Medicine News:Health News:Study shows adverse drug events reported to the FDA have significantly increased 2Health News:Vitamin D Supplements May Lengthen Life 2Health News:UCSF animal care facility receives top accreditation 2Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... visual acuity system allows you access to ... II. The system includes 10 different optotypes, ... and animated characters. Random character sequencing eliminates ... letter, single line and multiple line selection ...
... Light Probes provide the surgeon with an ... interface to be easily visualized through the ... effect and light scatter technique, the surgeon ... deposits, flap edge folds, corneal flap striae ...
Medicine Products: